Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2016135138) OXOQUINOLINE DERIVATIVES AS MTH1 INHIBITORS FOR THE THERAPY OF CANCER
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2016/135138 International Application No.: PCT/EP2016/053766
Publication Date: 01.09.2016 International Filing Date: 23.02.2016
IPC:
A61K 31/473 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
473
ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH [AT/AT]; Lazarettgasse 14 AKH BT 25.3 1090 Wien, AT
Inventors:
HUBER, Kilian; AT
Agent:
VOSSIUS & PARTNER PATENTANWÄLTE RECHTSANWÄLTE MBB; Siebertstraße 3 81675 München, DE
Priority Data:
15156185.923.02.2015EP
Title (EN) OXOQUINOLINE DERIVATIVES AS MTH1 INHIBITORS FOR THE THERAPY OF CANCER
(FR) DÉRIVÉS D'OXOQUINOLÉINE EN TANT QU'INHIBITEURS DE MTH1 POUR LA THÉRAPIE DU CANCER
Abstract:
(EN) The present invention relates to oxoquinoline derivatives of formula (I) for use as medicaments as well as pharmaceutical compositions comprising these compounds, particularly for use as inhibitors of MTH1 and for use in the treatment or prevention of cancer.
(FR) La présente invention concerne des dérivés d'oxoquinoléine de formule (I) pour leur utilisation en tant que médicaments ainsi que des compositions pharmaceutiques comprenant ces composés, en particulier pour leur utilisation en tant qu'inhibiteurs de MTH1 et pour leur utilisation dans le traitement ou la prévention du cancer.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)